Imaging gene-substance interactions
Standard
Imaging gene-substance interactions : the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. / Kirsch, Peter; Reuter, Martin; Mier, Daniela; Lonsdorf, Tina; Stark, Rudolf; Gallhofer, Bernd; Vaitl, Dieter; Hennig, Jürgen.
In: NEUROSCI LETT, Vol. 405, No. 3, 25.09.2006, p. 196-201.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Imaging gene-substance interactions
T2 - the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward
AU - Kirsch, Peter
AU - Reuter, Martin
AU - Mier, Daniela
AU - Lonsdorf, Tina
AU - Stark, Rudolf
AU - Gallhofer, Bernd
AU - Vaitl, Dieter
AU - Hennig, Jürgen
PY - 2006/9/25
Y1 - 2006/9/25
N2 - Dopamine is known as the main neurotransmitter modulating the activation of the reward system of the brain. The DRD2 TaqIA polymorphism is associated with dopamine D2 receptor density which plays an important role in the context of reward. Persons carrying an A1 allele have a lower D2 receptor density and a higher risk to show substance abuse. The present study was designed to investigate the influence of the DRD2 TaqIA polymorphism and the selective D2 receptor agonist bromociptine on the activation of the reward system by means of functional magnetic resonance imaging (fMRI). In a double-blind crossover study with 24 participants we found an increase of reward system activation from placebo to bromocriptine only in subjects carrying the A1 allele. Furthermore, only A1 carrier showed an increase of performance under bromocriptine. The results are interpreted as reflecting a specific sensitivity for dopamine agonists in persons carrying an A1 allele and may complement actual data and theories of the development of addiction disorders postulating a higher genetic risk for substance abuse in carrier of the A1 allele.
AB - Dopamine is known as the main neurotransmitter modulating the activation of the reward system of the brain. The DRD2 TaqIA polymorphism is associated with dopamine D2 receptor density which plays an important role in the context of reward. Persons carrying an A1 allele have a lower D2 receptor density and a higher risk to show substance abuse. The present study was designed to investigate the influence of the DRD2 TaqIA polymorphism and the selective D2 receptor agonist bromociptine on the activation of the reward system by means of functional magnetic resonance imaging (fMRI). In a double-blind crossover study with 24 participants we found an increase of reward system activation from placebo to bromocriptine only in subjects carrying the A1 allele. Furthermore, only A1 carrier showed an increase of performance under bromocriptine. The results are interpreted as reflecting a specific sensitivity for dopamine agonists in persons carrying an A1 allele and may complement actual data and theories of the development of addiction disorders postulating a higher genetic risk for substance abuse in carrier of the A1 allele.
KW - Adolescent
KW - Adult
KW - Brain
KW - Bromocriptine
KW - Cross-Sectional Studies
KW - Dopamine Agonists
KW - Double-Blind Method
KW - Feedback, Psychological
KW - Female
KW - Humans
KW - Image Processing, Computer-Assisted
KW - Magnetic Resonance Imaging
KW - Male
KW - Oxygen
KW - Polymorphism, Genetic
KW - Reaction Time
KW - Receptors, Dopamine D2
KW - Reverse Transcriptase Polymerase Chain Reaction
KW - Reward
U2 - 10.1016/j.neulet.2006.07.030
DO - 10.1016/j.neulet.2006.07.030
M3 - SCORING: Journal article
C2 - 16901644
VL - 405
SP - 196
EP - 201
JO - NEUROSCI LETT
JF - NEUROSCI LETT
SN - 0304-3940
IS - 3
ER -
